-

BITT To Present Update on CD40 Program at AAI 2023

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today that the company will be presenting new data from its CD40 program at Immunology2023, the annual meeting of the American Association of Immunologists. Dominant CD40 Receptor (CD40R) Antagonist Antibodies as Novel Approach to Treating Autoimmune Diseases, will be presented in the Late Breaking Immune Mechanisms of Human Disease session on Sunday May 14th from 2:30 - 3:45 PM.

“We are excited to have preclinical data on our second target for the DOMAb platform. Our CD40 antagonist share the novel characteristics of our TNFR2 antagonists that are moving into the clinic this year,” said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT.

About Boston Immune Technologies and Therapeutics

Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA-based company developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease based on the company’s DOMab™ platform. BITT is initiating clinical trials for BIR2101, its lead candidate, which is a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT is also developing additional antibodies targeting TNF superfamily receptors for indications in inflammation, oncology and infectious disease. Learn more at: www.bostonimmunetech.com.

Contacts

Karl Schmieder
karl@messaginglab.com
(646) 515-3392

Boston Immune Technologies and Therapeutics, Inc.


Release Versions
Hashtags

Contacts

Karl Schmieder
karl@messaginglab.com
(646) 515-3392

More News From Boston Immune Technologies and Therapeutics, Inc.

BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical Trial

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today a sponsored research and exclusivity agreement with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies. MSRD will finance key non-human primate studies for the pre-clinical development of BITT’s CD40 antag...

BITT Announces NIH Award for Advancement of Anti-CD40 Antibody

BOSTON--(BUSINESS WIRE)--BITT, a biotech developing TNF Superfamily receptor antagonist antibodies has received NIH funding to support BITT’s CD40 antibody in Sjögren’s...

BITT Announces FDA Acceptance of IND for TNFR2 Antibody

BOSTON--(BUSINESS WIRE)--The FDA has cleared BITT’s IND application for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed/refractory Non-Hodgkin’s lymphomas...
Back to Newsroom